Connor, Clark & Lunn Investment Management (CC&L)’s Karyopharm Therapeutics KPTI Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$440K	Buy	79,081 +21,869	+38%	+$167K	﹤0.01%	1335
2025 Q4	$421K	Buy	+57,212	New	+$350K	﹤0.01%	1331
2024 Q2	–	Sell	-5,088	Closed	-$115K	–	1535
2024 Q1	$115K	Buy	5,088 +340	+7%	+$5.96K	﹤0.01%	1455
2023 Q4	$61.6K	Buy	4,748 +2,396	+102%	+$32.3K	﹤0.01%	1334
2023 Q3	$47.3K	Sell	2,352 -147	-6%	-$3.3K	﹤0.01%	1321
2023 Q2	$67.1K	Sell	2,499 -9,998	-80%	-$431K	﹤0.01%	1262
2023 Q1	$729K	Sell	12,497 -16,322	-57%	-$806K	﹤0.01%	798
2022 Q4	$1.47M	Buy	28,819 +18,457	+178%	+$1.28M	0.01%	618
2022 Q3	$849K	Buy	10,362 +7,297	+238%	+$545K	0.01%	693
2022 Q2	$207K	Buy	+3,065	New	+$281K	﹤0.01%	932
2019 Q3	–	Sell	-3,845	Closed	-$346K	–	1023
2019 Q2	$346K	Sell	3,845 -4,885	-56%	-$392K	﹤0.01%	796
2019 Q1	$765K	Buy	+8,730	New	+$968K	0.01%	585
2016 Q2	–	Sell	-1,820	Closed	-$244K	–	901
2016 Q1	$244K	Sell	1,820 -920	-34%	-$102K	﹤0.01%	687
2015 Q4	$545K	Buy	2,740 +68	+3%	+$14.7K	﹤0.01%	526
2015 Q3	$422K	Sell	2,672 -375	-12%	-$100K	﹤0.01%	550
2015 Q2	$1.24M	Buy	3,047 +107	+4%	+$46.2K	0.01%	303
2015 Q1	$1.35M	Buy	2,940 +2,207	+301%	+$951K	0.01%	274
2014 Q4	$412K	Buy	+733	New	+$416K	﹤0.01%	420